Just a decade ago, the outlook for someone diagnosed with lung cancer was grim. Today, the survival rates have dramatically increased. In fact, the mortality rate for lung cancer is falling at a rate that exceeds every other cancer — and the numbers continue to drop every year.
This momentum is a direct result of groundbreaking research and clinical trials. We now utilize therapies that target specific types of lung cancer. We have personalized immunotherapies that reignite the body’s natural defenses. We have advanced screening technology to detect lung cancer biomarkers at the earliest stages. Lung cancer vaccines are on the horizon.
A lung cancer diagnosis now comes with more hope, and that’s due to the collective effort of researchers, clinicians, and patients who join clinical trials. Together, we're advancing our understanding of lung cancer to make treatment more impactful for everyone.
